Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients

<p>Abstract</p> <p>Background</p> <p>Activity of cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor, is largely attributed to its direct antiproliferative and proapoptotic effects. Antibody-dependent cell-mediated cytotoxicity (ADCC...

Full description

Bibliographic Details
Main Authors:	Devière Jacques, Lemmers Arnaud, Demetter Pieter, De Schutter Jef, Nagy Nathalie, Maréchal Raphaël, Salmon Isabelle, Tejpar Sabine, Van Laethem Jean-Luc
Format:	Article
Language:	English
Published:	BMC 2010-06-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/10/340

Similar Items

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2020-06-01)

Implementation of colonoscopy quality monitoring in a Belgian university hospital with integrated computer-based extraction of adenoma detection rate
by: Sohaib Ouazzani, et al.
Published: (2021-02-01)

Cetuximab for the first-line treatment of metastatic colorectal cancer
by: C Meads, et al.
Published: (2010-05-01)

Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01)

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
by: Salvatore Siena, et al.
Published: (2013-01-01)

Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
by: A. D. Darenskaya, et al.
Published: (2018-11-01)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
by: Mohamedtaki A Tejani, et al.
Published: (2010-06-01)

Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer
by: Hao Zhuang, et al.
Published: (2011-12-01)

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
by: Cals Laurent, et al.
Published: (2009-04-01)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
by: Adriana Camargo Carvalho, et al.
Published: (2017-01-01)

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
by: Jakob V Schou, et al.
Published: (2014-01-01)

Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
by: Jacques Bernier
Published: (2011-12-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
by: P Tappenden, et al.
Published: (2007-03-01)

KRAS mutations as a predictor of response to Cetuximab in metastatic colorectal cancer patients
by: Li-Chen Yen, et al.
Published: (2010)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
by: Candice Hober, et al.
Published: (2021-05-01)

Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells: What Do We Know So Far?
by: Pieter Demetter, et al.
Published: (2021-03-01)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.
by: Kimio Yonesaka, et al.
Published: (2015-01-01)

Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab
by: Jeffrey Chi, et al.
Published: (2020-01-01)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
by: Per Pfeiffer, et al.
Published: (2008-12-01)

Cost-effectiveness analysis of cetuximab in treatment of metastatic colorectal cancer in Iranian pharmaceutical market
by: Majid Davari, et al.
Published: (2015-01-01)

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
by: Teresa Magnes, et al.
Published: (2017-01-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

First-line targeted therapies in the treatment of metastatic colorectal cancer &ndash; role of cetuximab
by: Giuseppe Tonini, et al.
Published: (2009-04-01)

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
by: Nemecek R, et al.
Published: (2016-07-01)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literature
by: Grisanti Salvatore, et al.
Published: (2008-09-01)

Influence of HER2 Overexpression on Response to Cetuximab in Patients with Metastatic Colorectal Cancer, Tehran, Iran
by: Rambod MOZAFARI, et al.
Published: (2018-06-01)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
by: Sato Y, et al.
Published: (2015-11-01)

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
by: Enrique Aranda, et al.
Published: (2021-04-01)

Treatment of Pancreatic Cancer: What Can We Really Predict Today?
by: Jean-Baptiste Bachet, et al.
Published: (2011-02-01)

Lateral duodenal wall perforation due to plastic biliary stent migration: a case series of endoscopic closure
by: Marc-Andre Bureau, et al.
Published: (2020-04-01)

Blefarite e tricomegalia induzidas pelo cetuximabe Blepharitis and trichomegaly induced by cetuximab
by: Paulo Ricardo Criado, et al.
Published: (2010-12-01)

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis
by: Rong Li, et al.
Published: (2020-05-01)

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
by: Nico B. Volz, et al.
Published: (2020-10-01)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
by: John Pradeep Veluchamy, et al.
Published: (2016-01-01)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
by: Shinya Uozumi, et al.
Published: (2018-12-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Cheng, C.-L, et al.
Published: (2022)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01)